File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Clinical outcome for lymphoepithelioma-like carcinoma of the lung cancer after chemoradiotherapy

TitleClinical outcome for lymphoepithelioma-like carcinoma of the lung cancer after chemoradiotherapy
Authors
Issue Date2003
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/lungcan
Citation
The 10th World Conference on Lung Cancer (WCLC 2003), Vancouver, Canada, 10–14 August 2003. In Lung Cancer, v. 41 suppl. 2, p. S146, abstract no. P-216 How to Cite?
AbstractBACKGROUND: Lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus-associated undifferentiated carcinoma, is a rare form of non-small cell lung cancer. It predominantly affects young non-smoking Asians and is frequently believed to be resectable. However, there has only been limited experience with the use of palliative chemotherapy and radiotherapy in treating advanced LELC of the lung. STUDY OBJECTIVES: To evaluate the tumor response, time to progression and survival of patients with advanced LELC of the lung who received chemoradiotherapy. Design and patients: We prospectively recruited cases of LELC of the lung with a standard clinical protocol. Patients with confirmed advanced LELC of the lung were given chemoradiotherapy treatment. SETTING: A tertiary respiratory referral center. RESULTS: There were 10 patients (5 males, age 47 f 9.8 years, median follow-up 22 months) with advanced LELC of the lung (1, 4, and 5 patients at TNM stage IIIA, 1118, and IV) who received systemic chemotherapy and radiotherapy. The primary chemotherapy regimen comprised of 5- fluorouracil/leucovorin/cisplatin (FLP). The response rates to FLP were 60% partial response, 10% stable disease, and 30% progressive disease. Eight patients were given local radiotherapy. Five patients received salvage chemotherapy when disease progressed after primary chemotherapy. The overall median survival was 23.4 & 4.7 months. CONCLUSION: The encouraging response to combination chemotherapy (FLP) supports its use, along with radiotherapy, in unresectable LELC of the lung.
DescriptionThis journal suppl. entitled: Abstract of the 10th World Conference on Lung Cancer
Persistent Identifierhttp://hdl.handle.net/10722/102055
ISSN
2015 Impact Factor: 3.767
2015 SCImago Journal Rankings: 1.923

 

DC FieldValueLanguage
dc.contributor.authorHo, JCMen_HK
dc.contributor.authorLam, WKen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorWong, MPen_HK
dc.contributor.authorTsang, KWTen_HK
dc.date.accessioned2010-09-25T20:15:15Z-
dc.date.available2010-09-25T20:15:15Z-
dc.date.issued2003en_HK
dc.identifier.citationThe 10th World Conference on Lung Cancer (WCLC 2003), Vancouver, Canada, 10–14 August 2003. In Lung Cancer, v. 41 suppl. 2, p. S146, abstract no. P-216en_HK
dc.identifier.issn0169-5002en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102055-
dc.descriptionThis journal suppl. entitled: Abstract of the 10th World Conference on Lung Cancer-
dc.description.abstractBACKGROUND: Lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus-associated undifferentiated carcinoma, is a rare form of non-small cell lung cancer. It predominantly affects young non-smoking Asians and is frequently believed to be resectable. However, there has only been limited experience with the use of palliative chemotherapy and radiotherapy in treating advanced LELC of the lung. STUDY OBJECTIVES: To evaluate the tumor response, time to progression and survival of patients with advanced LELC of the lung who received chemoradiotherapy. Design and patients: We prospectively recruited cases of LELC of the lung with a standard clinical protocol. Patients with confirmed advanced LELC of the lung were given chemoradiotherapy treatment. SETTING: A tertiary respiratory referral center. RESULTS: There were 10 patients (5 males, age 47 f 9.8 years, median follow-up 22 months) with advanced LELC of the lung (1, 4, and 5 patients at TNM stage IIIA, 1118, and IV) who received systemic chemotherapy and radiotherapy. The primary chemotherapy regimen comprised of 5- fluorouracil/leucovorin/cisplatin (FLP). The response rates to FLP were 60% partial response, 10% stable disease, and 30% progressive disease. Eight patients were given local radiotherapy. Five patients received salvage chemotherapy when disease progressed after primary chemotherapy. The overall median survival was 23.4 & 4.7 months. CONCLUSION: The encouraging response to combination chemotherapy (FLP) supports its use, along with radiotherapy, in unresectable LELC of the lung.-
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/lungcanen_HK
dc.relation.ispartofLung Canceren_HK
dc.rightsLung Cancer. Copyright © Elsevier Ireland Ltd.en_HK
dc.titleClinical outcome for lymphoepithelioma-like carcinoma of the lung cancer after chemoradiotherapyen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0169-5002&volume=41 &issue=suppl 2&spage=S146&epage=&date=2003&atitle=Clinical+outcome+for+lymphoepithelioma-like+carcinoma+of+the+lung+cancer+after+chemoradiotherapy,+the+10th+World+Congress+on+Lung+Canceren_HK
dc.identifier.emailHo, JCM: jhocm@hku.hken_HK
dc.identifier.emailLam, WK: lamwk@hku.hken_HK
dc.identifier.emailLam, B: lambing@HKUCC.hku.hken_HK
dc.identifier.emailWong, MP: mwpik@hkucc.hku.hken_HK
dc.identifier.emailTsang, KWT: kwttsang@hku.hken_HK
dc.identifier.authorityHo, JCM=rp00258en_HK
dc.identifier.authorityWong, MP=rp00348en_HK
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0169-5002(03)92185-4-
dc.identifier.hkuros86401en_HK
dc.identifier.volume41-
dc.identifier.issuesuppl. 2-
dc.identifier.spageS146, abstract no. P-216en_HK
dc.identifier.epageS146, abstract no. P-216-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats